• Explore /
  • Poster
  • / Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in <em>FGFR3</em>-altered advanced/metastatic urothelial carcinoma (aUC).

Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC).

Abstract Poster

Authors

Yung Lyou

Yung Lyou

City of Hope Comprehensive Cancer Center, Duarte, CA

Yung Lyou , Petros Grivas , Jonathan E. Rosenberg , Jean H. Hoffman-Censits , David I. Quinn , Daniel Peter Petrylak , Matt D. Galsky , Ulka N. Vaishampayan , Ugo De Giorgi , Howard A. Burris III, Jessica Rearden , Yining Ye , Hao Wang , Susan Moran , Siamak Daneshmand , Dean F. Bajorin , Sumanta K. Pal , Sumati Gupta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Other

Clinical Trial Registration Number

NCT01004224

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 576)

Abstract #

576

Poster Bd #

M13

Abstract Disclosures

Similar Posters

First Author: Yung Lyou

First Author: Nazli Dizman

First Author: Andrea Necchi

First Author: Ye Guo